Saturday 17 October 2026 Export SMTI’s income statement to Excel — free account

Sanara MedTech Inc.

SMTI Healthcare Medical Instruments & Supplies

Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 9.04%, EPS grew 78.3%, free cash flow grew 131.3% and total debt rose 5.11%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

33.14 1.95 −5.56%

Follow SMTI

Alert me

Market cap: $322.4M
P/E: 0.0×
Fwd P/E: 125×
Dividend yield: —
F-score: 4/9
Altman Z: 2.35
Beneish M: −3.22
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 43.67%

Capital & Financial Ratios $m

Market Cap 322.40

Revenue 109.81

Net Income (32.02)

Free Cash Flow 4.50

Net Debt 31.06

Current Ratio 2.58

Debt/Equity 5.86

P/E ratio 0.00

Fwd P/E 125.00

P/S ratio 2.61

P/B ratio 36.18

Past 5Y EPS Growth —

This Y EPS Growth 480.00%

Next Y EPS Growth 207.89%

Next Y revenue growth 13.07%

Next 5Y EPS Growth (8.82%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 42.18%

10-year low 10-year high

P/B against its own 10 years 91.93%

10-year low 10-year high

EV/Sales against its own 10 years 42.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	16	17	15
Receivables	9	12	12	13
Inventory	5	3	4	3
Other	—	—	—	—
	19	33	34	32

	2023	2024	2025	Q'26
Payables	2	2	2	1
ST’ Debt	1	—	—	—
Other	1	—	0	—
	14	15	19	12

Compound Annual Growth %

	10y	5y	3y
Sales	40.78%	45.92%	31.02%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.30%	(47.81%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	28	28	—	—	—
’25	23	26	26	28	103
’24	19	20	22	26	87
’23	16	16	16	18	65
’22	8	10	13	15	46
’21	5	6	6	7	24
’20	4	3	4	5	16

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	2	—	—	—
’25	(2)	3	2	4	7
’24	(2)	(1)	2	1	0
’23	(2)	(2)	1	(1)	(3)
’22	(2)	(1)	(2)	(1)	(6)
’21	(1)	0	(1)	(2)	(5)
’20	(2)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	2	—	—	—
’25	(4)	1	1	4	2
’24	(2)	(1)	2	1	0
’23	(2)	(2)	1	(1)	(4)
’22	(2)	(3)	0	(1)	(6)
’21	(1)	0	(2)	(2)	(6)
’20	(3)	(1)	(1)	(1)	(6)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.05	(0.05)	—	—	—
’25	(0.41)	(0.23)	(3.40)	(0.19)	(4.36)
’24	(0.21)	(0.41)	(0.34)	(0.18)	(1.14)
’23	(0.14)	(0.22)	(0.13)	(0.03)	(0.52)
’22	(0.41)	0.09	(0.18)	(0.51)	(1.00)
’21	(0.17)	(0.16)	(0.27)	(0.48)	(1.08)
’20	(0.39)	(0.18)	(0.18)	(0.04)	(0.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	2.00	4.00	2.00	2.00	7.04	21.30	17.41	26.06	26.00	18.90	Analyst estimates 2026–2028 Powerpack
	High	9.00	10.00	75.00	16.37	53.85	49.70	46.85	50.18	43.25	38.68
People
People	Employees	12	18	21	40	41	68	103	108	141	108
	Revenue/emp, $m	0.46	0.35	0.42	0.29	0.38	0.36	0.45	0.60	0.61	0.95
Income, $m
Income, $m	Revenue	6	6	9	12	16	24	46	65	87	103
	Gross margin, %	82.87	87.22	90.29	89.72	89.63	90.43	86.12	87.92	90.61	92.71
	EBT	0	0	0	(3)	(4)	(8)	(14)	(4)	(2)	0
	EBT margin, %	(7.55)	5.25	2.00	(24.10)	(28.52)	(33.11)	(30.40)	(6.83)	(2.24)	(0.38)
	Net income	0	0	0	(3)	(4)	(8)	(8)	(4)	(10)	(38)
	Depreciation	0	0	0	0	0	1	2	4	5	4
Per share, $
Per share, $	Revenue	5.07	5.66	4.24	5.52	2.72	3.29	5.80	7.85	10.22	11.96
	Earnings	(0.38)	0.00	(0.25)	(1.32)	(0.76)	(1.08)	(1.00)	(0.52)	(1.14)	(4.36)
	Cash flow	0.38	(0.13)	0.25	(1.02)	(0.70)	(0.66)	(0.70)	(0.39)	0.00	0.79
	Capex	0.00	(0.08)	(0.01)	(0.80)	(0.29)	(0.10)	(0.09)	(0.03)	(0.03)	(0.53)
	Free cash flow	0.37	(0.20)	0.24	(1.82)	(0.99)	(0.76)	(0.80)	(0.42)	(0.03)	0.25
	Book value	(0.39)	0.09	0.28	3.00	1.02	4.11	5.28	5.39	4.59	0.69
	Shares, m	1	1	2	2	6	7	8	8	8	9
Valuation, ×
Valuation, ×	P/E	0.00	26.93	37.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	1.08	1.06	0.71	2.92	18.36	8.99	6.99	5.22	3.25	1.95
	P/B	0.00	0.00	0.00	0.00	49.00	7.20	7.68	7.60	7.24	33.96
	EV/Sales	1.18	1.18	0.86	2.49	18.36	8.23	6.81	5.29	3.43	2.25
	EV/FCF	(1.09)	(43.62)	15.39	(7.50)	(50.40)	(35.71)	(49.54)	(83.57)	(348.62)	106.57
Cash, $m
Cash, $m	Operating cash flow	0	0	1	(2)	(4)	(5)	(6)	(3)	0	7
	Capex	0	0	0	(2)	(2)	(1)	(1)	0	0	(5)
	Free cash flow	0	0	0	(4)	(6)	(6)	(6)	(4)	0	2
Balance, $m
Balance, $m	Working capital	1	0	1	6	1	19	8	5	18	15
	Total debt	2	1	—	2	0	0	1	10	31	46
	Net debt	1	1	0	(5)	0	(18)	(8)	5	15	29
	Shareholders’ equity	0	0	1	6	6	30	42	45	39	6
Returns, %
Returns, %	ROA	(38.03)	8.76	2.25	(43.88)	(41.60)	(34.28)	(16.29)	(6.38)	(11.93)	(46.65)
	ROIC	(47.04)	8.97	32.30	(122.50)	(53.64)	(38.66)	(23.30)	(5.36)	1.46	12.92
	ROE	40.41	(18.92)	(0.77)	35.72	(1,007.96)	(44.02)	(22.09)	(9.97)	(23.15)	(167.53)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AVR Anteris Technologies Global Corp.	$619.8M	— (loss-making)	—	+63.27% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.91%	(3,072.05%)	Compare
ANGO AngioDynamics, Inc.	$487.0M	— (loss-making)	— (loss-making)	+6.87% (above 0%: growing)	n/m	+5.62% (above 0%: growing)	59.37%	(9.02%)	Compare
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%	Compare
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
Median of peers	$353.2M	13.8×	23.5×	+2.47%	−10.64%	−49.63%	55.79%	17.29%

All 55 Medical Instruments & Supplies stocks →

Sanara MedTech Inc. (SMTI) key facts

Strength: Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024.
Sanara MedTech Inc. (SMTI) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SMTI traded at $33.14, a market capitalization of $322.4 million.
Return on equity was −167.5% and debt-to-equity 5.86.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.35 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.